ARIA Share Price

Open 23.95 Change Price %
High 23.99 1 Day 0.04 0.17
Low 23.94 1 Week 0.00 0.00
Close 23.99 1 Month 0.00 0.00
Volume 7192149 1 Year 16.63 225.95
52 Week High 23.99
52 Week Low 6.47
ARIA Important Levels
Resistance 2 24.04
Resistance 1 24.02
Pivot 23.97
Support 1 23.96
Support 2 23.94
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
SIRI 5.07 0.00%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
ESSX 0.22 69.23%
MYRX 0.08 60.00%
CGEI 0.35 59.09%
LOCM 0.09 50.00%
RITT 0.03 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
CARV 4.90 22.81%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA)

ARIA Technical Analysis 5
As on 15th Feb 2017 ARIA Share Price closed @ 23.99 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 11.34 & Strong Buy for SHORT-TERM with Stoploss of 18.18 we also expect STOCK to react on Following IMPORTANT LEVELS.
ARIA Target for April
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
ARIA Other Details
Segment EQ
Market Capital 3671460096.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.ariad.com
ARIA Address
ARIA
26 Landsdowne Street
Cambridge, MA 02139
United States
Phone: 617-494-0400
Fax: 617-494-8144
Interactive Technical Analysis Chart ARIAD Pharmaceuticals, Inc. ( ARIA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on ARIAD Pharmaceuticals, Inc.
ARIA Business Profile
ARIAD Pharmaceuticals, Inc. (ARIAD), incorporated on on April 12, 1991, is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients. ARIAD’s first medicine, Iclusig, is approved in the United States for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant or intolerant to prior TKI therapy. As of January 11, 2013, additional clinical trials of Iclusig in other cancers were ongoing. As of January 11, 2013, ARIAD also studied AP26113, another molecularly targeted medicine, in certain forms of lung cancer. As of January 11, 2013, the Company’s pipeline contained four compounds: ponatinib, AP26113, ridaforolimus and AP1903. AP26113 is a potent dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). AP1903 is a dimerizer drug licensed to Bellicum Pharmaceuticals, Inc. In December 2012, the Company was granted accelerated approval of Iclusig ponatinib for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI therapy. Ponatinib is a BCR-ABL inhibitor that also selectively inhibits certain other tyrosine kinases in preclinical studies, including FLT3, RET, KIT, and the members of the FGFR, PDGFR and VEGFR families of kinases. The EPIC (Evaluation of Ponatinib versus Imatinib inChronic Myeloid Leukemia) trial is designed to provide definitive clinical data to support regulatory approval of ponatinib in treatment-nave CML patients. The PACE (Ponatinib Ph+ ALL and CML Evaluation) trial is a pivotal Phase 2 clinical trial of the Company’s investigational pan-BCR-ABL inhibitor, ponatinib (formerly AP24534).